Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study

Autor: Pols, Huib, Felsenberg, D, Hanley, DA, Stepán, J, Muñoz-Torres, M, Wilkin, TJ, Qin-sheng, G, Galich, AM, Vandormael, K, Yates, AJ, Stych, B, Fosamax Int. Trial st.gr.,

Publikováno v: Osteoporosis International, 9, pp. 461-468
Osteoporosis International, 9, 461-468
Osteoporosis International, 9, 461-468. Springer London

This randomized, double-masked, placebo-controlled trial evaluated the safety, tolerability and effects on bone mineral density (BMD) of alendronate in a large, multinational population of postmenopausal women with low bone mass. At 153 centers in 34

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f55c676d5910355a3e23800cd4db41
https://doi.org/10.1007/pl00004171